Inventiva S.A. American Depository Shares (IVA)

Inventiva, a clinical-stage biopharmaceutical company, will participate in multiple investor conferences in September 2025, including events in New York, Lyon, Brussels, and a virtual forum, to discuss its MASH treatment research.

Paramount Global shares jumped 7.5% in pre-market trading after the company announced a $28 billion merger deal with Skydance Media to create a new entity called 'New Paramount'. Several other stocks also saw significant pre-market movements.

Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.